Summary
S09 Chart
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.
Sutro Biopharma Inc. Dividends
Sutro Biopharma Inc. Earnings
| 11 Aug 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 11 Aug 2025 (In 4 weeks) Date | | - Cons. EPS | - EPS |
| 12 May 2025 Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
Sutro Biopharma Inc. (S09) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Sutro Biopharma Inc. ever had a stock split?
Sutro Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jane Chung CEO | XFRA Exchange | US8693671021 ISIN |
| US Country | 269 Employees | - Last Dividend | - Last Split | 27 Sep 2018 IPO Date |
Overview
Sutro Biopharma, Inc. stands as a pivotal clinical-stage oncology company, distinguished by its innovative approach towards treating cancer. Established in 2003 and originally named Fundamental Applied Biology, Inc., the company has since evolved, situating its headquarters in South San Francisco, California. Sutro Biopharma is at the forefront of developing site-specific and novel-format antibody drug conjugates (ADC) through its proprietary cell-free protein synthesis platforms, XpressCF, and XpressCF+. These advancements are tailored to address the unmet needs within oncology, focusing on delivering cutting-edge treatments for patients battling cancer. Additionally, Sutro Biopharma actively engages in collaboration and license agreements with esteemed entities like Merck, Celgene Corporation, EMD Serono, and Astellas Pharma Inc., aiming to expand the horizons of its ADC technologies across various cancer targets and autoimmune disorders.
Products and Services
STRO-001: An innovative antibody drug conjugate (ADC) specifically targeting CD74, a cancer-associated antigen. Currently in Phase 1 clinical trials, STRO-001 is designed for patients suffering from multiple myeloma and non-Hodgkin lymphoma. This treatment exemplifies Sutro Biopharma's commitment to addressing cancers with a high unmet medical need through targeted therapy.
STRO-002: This ADC is directed against folate receptor-alpha, a therapeutic target associated with ovarian and endometrial cancers. STRO-002 is in Phase 1 clinical trials, representing a strategic focus on gynecological malignancies by engaging in cutting-edge research to provide novel treatment options for patients.
STRO-003: A pre-clinical product candidate, STRO-003 is an ADC targeting the anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential applications in the treatment of solid tumors. This initiative underscores Sutro Biopharma’s dedication to expanding its ADC portfolio into broader oncology indications.
Contact Information
